Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Issue 1 (July 2015)

• Record Type: Journal Article
• Authors: Wang-Lopez, Qian; Chalabi, Nassera; Abrial, Catherine; Radosevic-Robin, Nina; Durando, Xavier; Mouret-Reynier, Marie-Ange; Benmammar, Kheir-Eddine; Kullab, Sharif; Bahadoor, Mohun; Chollet, Philippe; Penault-Llorca, Frédérique; Nabholtz, Jean-Marc
• Is Part Of: Critical reviews in oncology/hematology. Volume 95:Issue 1(2015)
• Page Start: 88
• Page End: 104
• Publication Date: 2015-07
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2015.02.011
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0285">FDA uses pCR as an endpoint to support new drug accelerated approval for high-risk early breast cancer.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0290">Different pCR definitions exist in the literature.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0295">FDA recommands yPT0/Tis yPN0 as a pCR definition.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0300">pCR rates varies among the different BC subgroups: higher in luminal B, HER2+ and TNBC.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0305">pCR is predictive for DFS and OS in HER2+ and TNBC and even not clear in luminal BC.</p> </list-item> </list> </p> </sec> </abstract>